In a phase III trial, olokizumab—an anti‐IL‐6 monoclonal antibody—significantly improved ACR20 response rates at 12 weeks in RA patients with an inadequate response to methotrexate and demonstrated noninferiority to adalimumab [526]. Here, IL6 is linked to rheumatoid arthritis.